MS4A1 and B-cell non-Hodgkin lymphoma: The additional ADCC and CDC components are considered to be the reason why Fc‐competent Brainshuttle‐CD20 mAbs demonstrate more potent B cell killing in WBAs versus Fc‐silent Brainshuttle‐CD20 mAbs, whereas in B cell lymphoma assays that assessed direct B cell killing without immune effector functions, comparable efficacy was demonstrated between the two Brainshuttle‐CD20 mAbs.